{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-24-000107","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2024-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.962947+00:00","generated_at":"2026-06-01T07:43:57.678882+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunovant reports Q4 net loss $75.3M, cash $635M; plans 4-5 registrational IMVT-1402 studies by 2025","bullets":["Net loss $75.3M ($0.52/sh) for Q4 FY2024 vs $59.4M ($0.46/sh) YoY; FY net loss $259.3M ($1.88/sh).","Cash and equivalents $635M as of March 31, 2024; R&D expenses $66.1M in Q4.","Following FDA Type B meeting, on track to initiate 4-5 registrational studies for IMVT-1402 by March 31, 2025.","Batoclimab MG topline results expected by end of fiscal 2025; CIDP trial extended ~2 quarters before unblinding.","Composition-of-matter patent for IMVT-1402 issued with term through June 2043."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-24-000107","json":"https://secwatch.observer/filing/0001764013-24-000107.json","markdown":"https://secwatch.observer/filing/0001764013-24-000107.md","text":"https://secwatch.observer/filing/0001764013-24-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000107/0001764013-24-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000107/imvt-20240529.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:43:57.678882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}